A ligand screening method for targeting and activating VDR receptors in macrophages and its application

By screening and validating compounds that target and activate VDR receptors in macrophages, the problems of unstable efficacy and side effects of existing VDR-targeted therapies in AIH have been solved, enabling precise treatment of liver inflammation and fibrosis and providing a lead compound for novel AIH treatment.

CN123072489APending Publication Date: 2026-11-10THE FIRST AFFILIATED HOSPITAL OF WENZHOU MEDICAL UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202611343886.9
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2026-09-01
Publication Date
2026-11-10

AI Technical Summary

Technical Problem

Existing VDR-targeted therapies for autoimmune hepatitis (AIH) have significant individual variability in efficacy, substantial toxic side effects with long-term use, high relapse rates upon discontinuation, and a high number of refractory cases. Furthermore, traditional VDR agonists are prone to causing adverse reactions such as hypercalcemia. Differences in VDR sequences and functions among species limit the development of novel targeted drugs.

Method used

By establishing a database of natural product compounds derived from traditional Chinese medicine, and using protein structure molecular docking virtual screening and binding free energy analysis, compounds that target and activate VDR receptors in macrophages were screened out. Engineered exosomes were then constructed for in vitro activity evaluation and in vivo efficacy verification.

Benefits of technology

By screening out the highly effective and safe VDR agonist carvedin or its derivatives, macrophages were transformed from pro-inflammatory M1 type to anti-inflammatory M2 type, reducing liver inflammation and fibrosis, providing a precise treatment strategy for AIH, and avoiding the side effects of systemic immunosuppression.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN123072489A_ABST
    Figure CN123072489A_ABST
Patent Text Reader

Abstract

This invention discloses a method for screening ligands that target and activate VDR receptors in macrophages and its applications. The method includes establishing a database of natural product compounds derived from traditional Chinese medicine, virtual screening based on protein structure-based molecular docking, binding free energy analysis, in vitro activity assessment, construction and characterization of engineered exosomes, fluorescence imaging and tissue distribution, and in vivo efficacy evaluation. This invention established a database of natural products that regulate the spleen and stomach, and discovered novel ligands for VDR. Using these compounds, engineered exosomes were constructed to achieve liver-targeted delivery, saving costs, improving therapeutic efficacy, and ultimately obtaining drugs that can be further developed for the treatment of autoimmune hepatitis.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention relates to the field of drug screening technology, specifically to a ligand screening method for targeting and activating VDR receptors in macrophages and its application. Background Technology

[0002] Autoimmune hepatitis (AIH) is an immune-mediated, chronic, progressive inflammatory disease of hepatocellular carcinoma, characterized by elevated transaminases, hypergammaglobulinemia, positive autoantibodies, and interface hepatitis. It is more common in women, and its global prevalence is increasing annually. The pathogenesis of AIH is related to genetic susceptibility, immune imbalance, and environmental stimuli. Patients often experience symptoms such as fatigue and jaundice, and in advanced stages, it can progress to cirrhosis, severely impairing their quality of life. Currently, immunosuppressants such as glucocorticoids, azathioprine, and mycophenolate mofetil are commonly used in clinical practice, but these only partially alleviate the condition. They suffer from significant individual variability in efficacy, substantial long-term side effects, high relapse rates upon discontinuation, and refractory cases. There is an urgent clinical need for novel, highly effective, safe, and long-acting treatment strategies and targeted therapies.

[0003] Traditional Chinese medicine (TCM), with its advantages of multi-target holistic regulation and low side effects, has been gradually applied in the clinical treatment of autoimmune hepatitis (AIH). It can regulate liver immune inflammation, protect hepatocytes, and improve patient symptoms. However, its development is still constrained by insufficient evidence-based medicine and non-standardized syndrome differentiation. Current research confirms that the vitamin D receptor (VDR) is a core target regulating the pathological process of AIH. As a nuclear transcription factor, VDR can maintain liver immune homeostasis, regulate immune cell differentiation, inhibit the release of pro-inflammatory factors, inhibit hepatic stellate cell activation, reduce liver fibrosis, and enhance the anti-apoptotic and antioxidant capacity of hepatocytes. Furthermore, the VDR expression level in the liver tissue of AIH patients is closely related to disease activity; targeted activation of VDR can effectively alleviate liver inflammation and fibrosis.

[0004] Currently, VDR-targeted therapy is still in the exploratory stage. Traditional VDR agonists are prone to adverse reactions such as hypercalcemia, and the structural characteristics of the VDR ligand binding pocket can easily lead to off-target effects. In addition, the sequence and functional differences of VDRs among species greatly limit the research and development of novel targeted drugs. Natural products derived from traditional Chinese medicine have advantages such as structural diversity, high safety, and multi-target synergistic effects, making them a high-quality resource for developing novel VDR modulators for AIH.

[0005] Hepatic macrophages are the core hubs for the initiation of inflammation, disease progression, and development of liver fibrosis in autoimmune hepatitis (AIH). Their M1 pro-inflammatory phenotype can release large amounts of pro-inflammatory factors and activate T cells, exacerbating liver damage. Traditional immunosuppressive regimens are systemic immunosuppression, which can easily lead to risks such as infection and tumors. However, hepatic macrophages highly express VDR, and specific activation of VDR can inhibit the NF-κB pro-inflammatory pathway, promote the transformation of macrophages from the pro-inflammatory M1 type to the anti-inflammatory M2 type, upregulate the secretion of anti-inflammatory factors, and simultaneously promote the recruitment of regulatory T cells and delay liver fibrosis. This allows for precise anti-inflammatory treatment of lesions, avoiding the drawbacks of systemic immunosuppression, and represents a cutting-edge direction in the precision treatment of AIH. Summary of the Invention

[0006] The purpose of this invention is to overcome the shortcomings of the prior art by providing a ligand screening method for targeting and activating VDR receptors in macrophages and its application. This method can reduce the number of compounds, save costs, and improve screening efficiency, and can be used to further develop and utilize lead compounds for the treatment of AIH.

[0007] To address the aforementioned technical problems, this invention discloses a ligand screening method for targeting and activating VDR receptors in macrophages, comprising the following steps: Step S1: Establishment of a database of natural product compounds derived from traditional Chinese medicine Traditional Chinese medicine formulas that can regulate liver and gallbladder were screened from classical Chinese medicine texts, and the compounds in these formulas were annotated to obtain a compound library. Step S2: Virtual screening based on protein structure-based molecular docking Using the ligand-binding domain of VDR as the target, a compound library was screened using HTVS, SP and XP docking modes, combined with ADME features, to obtain ten potential compounds. Step S3: Combine with free energy analysis The binding free energy of the above ten potential compounds was analyzed and ranked from high to low to obtain the top five compounds with the highest binding free energy. Step S4: In vitro activity assessment The top five compounds obtained in step S3 are subjected to in vitro activity evaluation. The compounds with the best in vitro activity are ranked from high to low.

[0008] Furthermore, the compound with the best in vitro activity evaluation is subjected to validation experiments, specifically including the following steps: Step S5: Construction and characterization of engineered exosomes The compound with the best in vitro activity was co-incubated with human umbilical cord-derived exosomes to construct engineered exosomes, and their particle size and zeta potential were characterized. Step S6: Fluorescence Imaging and Tissue Distribution and In Vivo Efficacy Assessment The engineered exosomes labeled with fluorescent markers were injected into the tail vein of mice, and the images were taken using a small animal in vivo imaging system. The colocalization of macrophages and engineered exosomes was examined by immunofluorescence. The engineered exosomes were evaluated for efficacy in a Conacanopus protein-induced AIH mouse model.

[0009] Furthermore, the traditional Chinese medicine compound in step S1 includes at least one of the following: Sijunzi Decoction, Liujunzi Decoction, Fuzi Lizhong Pill, Lizhong Pill, Pingwei Powder, Tiaozhong Hewei Pill, Yiwei Decoction, Shashen Maidong Decoction with modifications, Baohe Pill, Zhishi Daozhi Pill, Chaihu Shugan Powder with modifications, Si Ni San combined with Zuojin Pill, Shenling Baizhu Powder, Wudan Weifu Decoction, and Guipi Decoction.

[0010] Furthermore, in step S2, the molecular docking pocket is the ligand-binding domain of VDR, and the target protein PDB ID is 1IE9; the screening parameter for ADME in step S2 is LogP<5.0.

[0011] Furthermore, the compound with the highest binding free energy in step S3 is carvitine or its derivative.

[0012] Furthermore, the in vitro activity assessment in step S4 includes VDR transcriptional activity assay and macrophage functional polarization assessment.

[0013] Furthermore, in the engineered exosome construction in step S5, the mass ratio of the compound with optimal in vitro activity evaluation to human umbilical cord-derived exosomes is 1:5 to 1:1, the co-incubation temperature is 24℃ to 37℃, the time is 0.5 to 2 hours, the ultracentrifugation conditions are 100,000 g to 120,000 g, the centrifugation time is 1 to 2 hours, the average particle size of the engineered exosomes is 102.3 to 120.5 nm, and the Zeta potential is -10.5 to -13.9 mV.

[0014] Furthermore, the fluorescent labeling in step S6 is a DIR dye labeling.

[0015] Furthermore, in the in vivo efficacy evaluation in step S6, the ConA-induced AIH mouse model was established by tail vein injection of ConA 5 ~ 20 mg / kg, and the dose of engineered exosomes was 50 ~ 200 μg / mouse.

[0016] The present invention also includes the application of the above method as a means of screening drugs for the treatment of autoimmune hepatitis from natural products.

[0017] Compared with the prior art, the present invention has the following beneficial effects: 1. A compound database targeting the regulation of hepatobiliary function was established, providing a compound library for screening VDR partial agonists, saving time and cost, and improving screening efficiency; through this virtual screening method, highly efficient selective regulators of VDR in macrophages can be obtained, which can be used to further develop novel drugs for the treatment of AIH.

[0018] 2. Through the screening method of the present invention, carvedin or its derivatives were quickly screened as drugs for the treatment of autoimmune hepatitis, and a new use for carvedin or its derivatives was discovered. Attached Figure Description

[0019] The present invention will be further described in detail below with reference to the accompanying drawings and specific embodiments, and the advantages of the present invention in the above and / or other aspects will become clearer.

[0020] Figure 1 For small molecule virtual screening targeting VDR receptors; Figure 2 For in vitro activity evaluation of TLZ-8 compounds; Figure 3 Characterization of TLZ-8 compound loaded onto exosomes; Figure 4 Engineered exosomes can target macrophages in the liver; Figure 5 Engineered exosomes can alleviate ConA-induced immune liver injury; Figure 6 A scoring comparison chart showing the docking of a self-built compound library with a commercial natural product compound library. Detailed Implementation

[0021] The embodiments of the present invention are described in detail below. These embodiments are implemented based on the technical solution of the present invention, and provide detailed implementation methods and specific operation processes. However, the scope of protection of the present invention is not limited to the following embodiments.

[0022] Unless otherwise stated, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art. While only preferred methods and materials have been described herein, any methods and materials similar or equivalent to those described herein may be used in the implementation or testing of this invention. It should be noted that any aspects of this invention not described in detail are conventional practices in the art and are not the focus of this invention.

[0023] The terms “comprising,” “including,” “having,” “containing,” etc., used in this invention are all open-ended terms, meaning that they include but are not limited to.

[0024] Unless otherwise specified, all instruments, reagents and consumables used in this invention are purchased from the market.

[0025] The following specific examples further illustrate the ligand screening method for targeting and activating VDR receptors in macrophages. Example

[0026] A method for screening ligands that target and activate VDR receptors in macrophages, comprising the following steps: S1: Establishment of a database of natural product compounds derived from traditional Chinese medicine Based on traditional Chinese medicine theory and clinical practice, compound Chinese medicine formulas that can regulate the liver and gallbladder were screened from *Taiping Huimin Heji Jufang*, *Piwei Lun*, *Jinkui Yaolue*, *Shanghan Lun*, and *Danxi Xinfa*. These included formulas such as Sijunzi Tang, Liujunzi Tang, Fuzi Lizhong Wan, Lizhong Wan, Pingwei San, Tiaozhong Hewei Wan, Yiwei Tang, Shashen Maidong Tang (modified), Baohe Wan, Zhishi Daozhi Wan, Chaihu Shugan San (modified), Sini San combined with Zuojin Wan, Shenling Baizhu San, Wudan Weifu Tang, and Guipi Tang. Single herbs with a usage frequency ≥2 were further screened, ultimately resulting in 128 herbs. The compounds in these compound formulas were annotated using the Traditional Chinese Medicine Systems Pharmacology Database (TCMSP), the Traditional Chinese Medicine Integrated Database (TCMID), and the Chinese Academy of Sciences Chemistry Database (CSDB). After removing duplicates, 8957 natural compounds were obtained.

[0027] S2: Virtual screening based on protein structure-based molecular docking Using the LBD of VDR as the target (PDB ID: 1IE9), molecular docking was performed on 8957 compounds: initial screening was conducted using high-throughput virtual screening (HTVS), followed by secondary screening using standard precision (SP) and extreme precision (XP) modes; combined with the ADME rule (LogP < 5.0), 10 potentially active compounds were finally screened out (named TLZ-1 to TLZ-10). The active group of TLZ-8 forms stable hydrogen bonds with key residues of VDR-LBD (Arg-274, Ser-237, Ser-278), further verifying its binding specificity (see [link to relevant documentation]). Figure 1 (Figure A in the text).

[0028] S3: Combining free energy analysis The MM-GBSA binding free energy of the 10 compounds obtained in step S2 was calculated (see [reference]). Figure 1(See Figure B in the table). The results showed that the binding free energy of TLZ-8 (ΔG Bind = -65.3 kcal / mol) was significantly lower than that of other compounds (such as TLZ-7 at -50.2 kcal / mol and TLZ-9 at -45.7 kcal / mol), indicating that it has the strongest affinity for VDR-LBD and the best binding stability with VDR-LBD. It is a potential VDR receptor agonist. TLZ-8 is carvedin or a derivative thereof.

[0029] S4: In vitro activity assessment The top 5 compounds with the highest binding free energy in step S3 (TLZ-1, TLZ-6, TLZ-7, TLZ-8, TLZ-10) were selected for in vitro validation from two dimensions: VDR transcriptional activity and macrophage functional polarization. (1) VDR transcriptional activity assay (luciferase reporter gene assay): 293T cells were divided into a Control group and TLZ-1~TLZ-10 treatment groups (100 nM). After transfection with a VDR-responsive luciferase reporter vector, the fluorescence intensity was detected (see [reference]). Figure 2 (See Figure A in the table). The results showed that compared with the Control group, TLZ-1 to TLZ-10 significantly enhanced VDR transcriptional activity; among them, TLZ-8 had the highest transcriptional activity (approximately 8.5 times that of the Control group), which was significantly better than other candidate compounds (TLZ-7 approximately 7.2 times and TLZ-10 approximately 5.6 times).

[0030] (2) Cytotoxicity (CCK-8 assay): After TLZ-8 treatment of RAW264.7 cells for 24 h, cell viability remained above 0.5% within the concentration range of 1 nM to 15625 nM (see [reference]). Figure 2 (Figure B in the diagram) showed no obvious cytotoxicity, meeting the concentration requirements for subsequent experiments.

[0031] (3) ROS level detection: The ROS level of LPS-induced M1 macrophages was significantly increased, while the ROS level of the TLZ-8 treatment group was significantly decreased, indicating that TLZ-8 can inhibit oxidative stress in macrophages (see Figure 2 (Figure C in the diagram).

[0032] (4) NO content determination (Griess method): The NO release in the LPS group (15.2 μM) was significantly higher than that in the Control group (1.2 μM), while the NO release in the TLZ-8 treatment group decreased to 2.8 μM (see Figure 2 (D diagram in the middle). (5) qPCR detection of inflammatory factors: The mRNA levels of pro-inflammatory factors (TNF-α, IFN-γ, iNOS, CD86, MHC2) were significantly upregulated in the LPS group, while the mRNA levels of these factors were significantly downregulated in the TLZ-8 treatment group (e.g., TNF-α mRNA decreased to 1.8, IFN-γ decreased to 2.1, see [link]). Figure 2 (Figure E in the diagram).

[0033] The above results confirm that TLZ-8 can effectively activate VDR transcriptional activity and polarize macrophages from the pro-inflammatory M1 type to the anti-inflammatory M2 type.

[0034] S5: Construction and Characterization of Engineered Exosomes TLZ-8 and human umbilical cord-derived exosomes (Exo) were co-incubated at a drug-to-exosome mass ratio of 1:5 to 1:1 for 0.5 to 2 h at 24°C to 37°C. Engineered exosomes (Exo@TLZ-8) were collected by ultracentrifugation (100,000 g to 120,000 g for 1 to 2 hours) and characterized. (1) Transmission electron microscopy (TEM) observation: Exo@TLZ-8 exhibits a typical cup-shaped structure (consistent with natural exosomes) and uniform particle size (see Figure 3 (Figure A in the text).

[0035] (2) Nanoparticle tracking analysis (NTA): The average particle size of Exo@TLZ-8 was 120.5 nm (peak at 120 nm), and the concentration was approximately 1.2 × 10⁻⁶. 10 particles / mL; no significant difference in particle size from natural exosomes (Exo) (see [link to relevant documentation]). Figure 3 (Figure B in the diagram).

[0036] (3) Zeta potential analysis: The Zeta potential of Exo@TLZ-8 is -10.5~-13.9 mV (see Figure 3 (Figure C in the figure) The small potential change indicates that TLZ-8 loading did not disrupt the surface charge stability of exosomes.

[0037] S6: Fluorescence Imaging and Tissue Distribution 50–200 μg of fluorescently labeled (DIR) engineered exosomes were injected via the tail vein, and images were taken using a small animal in vivo imaging system. Results showed that the fluorescence intensity in the liver region was significantly higher than that in the lungs, heart, spleen, and kidneys (see [link to results]). Figure 4Figure A in the figure shows that exosomes can target and accumulate in the liver (AIH lesion site). Immunofluorescence of liver tissue revealed that F4 / 80 (macrophage marker, green) and DAPI (nucleus, blue) were significantly co-localized in the liver tissue of the Exo@TLZ-8 group, confirming that exosomes were taken up by hepatic macrophages (see Figure A). Figure 4 (Figure B in the text) S7: In vivo efficacy assessment A ConA-induced AIH model was established (ConA was injected via the tail vein, 5-20 mg / kg), and three groups were set up: Control group (normal saline); ConA group (model group); and Exo@TLZ-8 group (Exo@TLZ-8 was injected via the tail vein, 100 ug / animal).

[0038] (1) Liver function index detection: Compared with the Control group, the serum ALT (680 U / L) and AST (160 U / L) levels in the ConA group were significantly increased; while the ALT (240 U / L) and AST (90 U / L) levels in the Exo@TLZ-8 group were significantly decreased (see Figure 5 Figure A in the figure shows that Exo@TLZ-8 can effectively improve liver damage in AIH mice.

[0039] (2) Liver tissue pathological sections: Control group: clear liver lobule structure, normal hepatocyte morphology; ConA group: extensive hepatocyte necrosis, with a large number of lymphocyte infiltration (see Figure 5 Figure B in the diagram); Exo@TLZ-8 group: reduced area of ​​hepatocyte necrosis and significantly reduced inflammatory infiltration (see Figure B in the diagram). Figure 5 (Figure B in the diagram).

[0040] S8: Comparative analysis of VDR molecular docking scores between self-built compounds and commercial natural product compound libraries. Compared with commercial natural product compound libraries, the number of compounds with a docking score <-9.0 in the self-built library was 5.18%, while that in commercial natural product compound libraries was 1.83%. The number of compounds with a docking score <-8.0 in the self-built library was 20.79%, while that in commercial natural product compound libraries was only 4.77% (see [link to documentation]). Figure 6 This demonstrates that the hit efficiency of VDR molecular docking using a self-built library is superior to that of commercial natural product compound libraries.

[0041] This invention relies on computer-aided drug design technology, takes VDR as the core target, and combines a self-built database of natural product small molecules. Through virtual screening methods such as molecular docking and binding free energy calculation, it screens novel VDR modulators with high selectivity and explores the immunomodulatory effects of lead compounds on macrophages. The aim is to provide a theoretical basis for the development of novel therapeutic candidate drugs for AIH.

[0042] This invention provides a method and application for ligand screening to target and activate VDR receptors in macrophages. Many methods and approaches exist for implementing this technical solution; the above description is merely a preferred embodiment of the invention. It should be noted that those skilled in the art can make various improvements and modifications without departing from the principles of this invention, and these improvements and modifications should also be considered within the scope of protection of this invention. All components not explicitly stated in this embodiment can be implemented using existing technologies.

Claims

1. A method for screening ligands that target and activate VDR receptors in macrophages, characterized in that, Includes the following steps: Step S1: Establishment of a database of natural product compounds derived from traditional Chinese medicine Traditional Chinese medicine formulas that can regulate liver and gallbladder were screened from classical Chinese medicine texts, and the compounds in these formulas were annotated to obtain a compound library. Step S2: Virtual screening based on protein structure-based molecular docking Using the ligand-binding domain of VDR as the target, a compound library was screened using HTVS, SP and XP docking modes, combined with ADME features, to obtain ten potential compounds. Step S3: Combine with free energy analysis The binding free energy of the above ten potential compounds was analyzed and ranked from high to low to obtain the top five compounds with the highest binding free energy. Step S4: In vitro activity assessment The top five compounds obtained in step S3 are subjected to in vitro activity evaluation. The compounds with the best in vitro activity are ranked from high to low.

2. The method according to claim 1, characterized in that, The compound with the best in vitro activity evaluation was subjected to validation experiments, specifically including the following steps: Step S5: Construction and characterization of engineered exosomes The compound with the best in vitro activity was co-incubated with human umbilical cord-derived exosomes to construct engineered exosomes, and their particle size and zeta potential were characterized. Step S6: Fluorescence Imaging and Tissue Distribution and In Vivo Efficacy Assessment The engineered exosomes labeled with fluorescent markers were injected into the tail vein of mice, and the images were taken using a small animal in vivo imaging system. The colocalization of macrophages and engineered exosomes was examined by immunofluorescence. The engineered exosomes were evaluated for efficacy in a Conacanopus protein-induced AIH mouse model.

3. The method according to claim 1, characterized in that, The traditional Chinese medicine compound in step S1 includes at least one of the following: Sijunzi Decoction, Liujunzi Decoction, Fuzi Lizhong Pill, Lizhong Pill, Pingwei Powder, Tiaozhong Hewei Pill, Yiwei Decoction, Shashen Maidong Decoction with modifications, Baohe Pill, Zhishi Daozhi Pill, Chaihu Shugan Powder with modifications, Si Ni San combined with Zuojin Pill, Shenling Baizhu Powder, Wudan Weifu Decoction, and Guipi Decoction.

4. The method according to claim 1, characterized in that, The molecular docking pocket in step S2 is the ligand-binding domain of VDR, and the target protein PDB ID is 1IE9; the screening parameter for ADME in step S2 is LogP<5.

0.

5. The method according to claim 1, characterized in that, The compound with the highest binding free energy in step S3 is carvitine or its derivative.

6. The method according to claim 1, characterized in that, The in vitro activity assessment in step S4 includes VDR transcriptional activity assay and macrophage functional polarization assessment.

7. The method according to claim 2, characterized in that, In step S5, during the construction of engineered exosomes, the mass ratio of the compound with optimal in vitro activity evaluation to human umbilical cord-derived exosomes is 1:5 to 1:

1. The co-incubation temperature is 24℃ to 37℃ for 0.5 to 2 hours, and the ultracentrifugation conditions are 100,000 g to 120,000 g for 1 to 2 hours. The average particle size of the engineered exosomes is 102.3 to 120.5 nm, and the Zeta potential is -10.5 to -13.9 mV.

8. The ligand screening method for targeting and activating VDR receptors in macrophages according to claim 2, characterized in that, The fluorescent labeling in step S6 is a DIR dye labeling.

9. The method according to claim 2, characterized in that, In the in vivo efficacy evaluation in step S6, the ConA-induced AIH mouse model was established by tail vein injection of ConA 5 ~ 20 mg / kg, and the dose of engineered exosomes was 50 ~ 200 μg / mouse.

10. The method according to claim 1 as an application for screening drugs for treating autoimmune hepatitis from natural products.